DTNBP1 and juvenile Huntington disease: These findings are in line with fingolimod's ability to counteract memory impairment in a dysbindin-1-deficient genetic model of cognitive deficits (48), a rat model of Huntington's disease (49), and a mouse model of Alzheimer's disease (50).